0.58

7.30% -0.0457

Elevation Oncology Inc (ELEV)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$0.6257

Offen:

$0.62

24-Stunden-Volumen:

2.37M

Relative Volume:

3.07

Marktkapitalisierung:

$34.29M

Einnahmen:

Nettoeinkommen (Verlust:

$-41.95M

KGV:

-0.162

EPS:

-3.58

Netto-Cashflow:

$-38.34M

1W Leistung:

-8.82%

1M Leistung:

-0.19%

6M Leistung:

-79.02%

1J Leistung:

+26.03%

1-Tages-Spanne:

$0.55

$0.66

1-Wochen-Bereich:

$0.55

$0.70

52-Wochen-Spanne:

$0.4401

$5.8299

Elevation Oncology Inc Stock (ELEV) Company Profile

Firmenname

Elevation Oncology Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

(716) 371-1125

Adresse

101 FEDERAL STREET, BOSTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-08-05

Neueste SEC-Einreichungen

ELEV's Discussions on Twitter

Vergleichen Sie ELEV mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ELEV Elevation Oncology Inc	0.58	34.29M	0	-41.95M	-38.34M	-0.83
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-05-31	Eingeleitet	Piper Sandler	Overweight
2024-05-14	Eingeleitet	Stephens	Overweight
2024-03-01	Eingeleitet	JMP Securities	Mkt Outperform
2023-05-30	Hochstufung	SVB Securities	Market Perform → Outperform
2021-12-23	Eingeleitet	H.C. Wainwright	Buy

Elevation Oncology Inc Aktie (ELEV) Neueste Nachrichten

Dec 16, 2024

Items Tagged with 'ESMO IO 2024' - BioWorld Online

Dec 16, 2024

Dec 14, 2024

Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 - The Eastern Progress Online

Dec 14, 2024

Dec 13, 2024

Elevation Oncology nominates HER3 ADC as development candidate - BioWorld Online

Dec 13, 2024

Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion - ShareCast

Dec 13, 2024

Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference - The Eastern Progress Online

Dec 13, 2024

Dec 12, 2024

Elevation Oncology Inc licences Synaffix BV’s ADC platform - European Biotechnology News

Dec 12, 2024

Synaffix out-licenses ADC technology to Elevation Oncology - The Pharma Letter

Dec 12, 2024

Elevation Oncology selects EO-1022 as HER3 ADC candidate - Investing.com

Dec 12, 2024

Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors - PR Newswire

Dec 12, 2024

Elevation Oncology Unveils Promising HER3 ADC Candidate for Multiple Cancer Types - StockTitan

Dec 12, 2024

Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online

Dec 12, 2024

Dec 05, 2024

Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024 - PR Newswire

Dec 05, 2024

Dec 04, 2024

Elevation Oncology Shares Tumble 39% On $50 Mln Stock-And-Warran… - Marketscreener.com

Dec 04, 2024

Nov 27, 2024

ELEVElevation Oncology, Inc. Latest Stock News & Market Updates - StockTitan

Nov 27, 2024

Five things for pharma marketers to know for Friday morning - MM+M Online

Nov 27, 2024

Nov 15, 2024

Logos Global Management LP Adjusts Stake in Elevation Oncology I - GuruFocus.com

Nov 15, 2024

OrbiMed Advisors LLC Increases Stake in Elevation Oncology Inc - GuruFocus.com

Nov 15, 2024

Biotechnology Value Fund L P's Strategic Acquisition in Elevatio - GuruFocus.com

Nov 15, 2024

Nov 12, 2024

Elevation Oncology's SWOT analysis: promising ADC stock faces key data readout - Investing.com

Nov 12, 2024

Nov 07, 2024

Goldman Sachs Group Inc's Strategic Acquisition in Elevation Onc - GuruFocus.com

Nov 07, 2024

Nov 06, 2024

Elevation Oncology’s Q3 2024 Highlights and Financial Report - TipRanks

Nov 06, 2024

Elevation Oncology's Cancer Drug Shows 43% Response Rate, Secures FDA Fast Track | ELEV Stock News - StockTitan

Nov 06, 2024

Nov 05, 2024

Ovarian Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Elevation Oncology Inc - GuruFocus.com

Nov 05, 2024

Nov 01, 2024

AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down - Zacks Investment Research

Nov 01, 2024

Oct 31, 2024

Merck Q3 Earnings & Sales Top, Stock Down on Lowered '24 View - Yahoo Finance

Oct 31, 2024

Oct 25, 2024

Alkermes' Q3 Earnings & Revenues Fall Shy Of Estimates, Stock Down - Barchart

Oct 25, 2024

Oct 22, 2024

AstraZeneca Receives CHMP's Approval for Wainzua in Europe - Zacks Investment Research

Oct 22, 2024

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies - Yahoo Canada Finance

Oct 22, 2024

Oct 19, 2024

SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies - MSN

Oct 19, 2024

Oct 17, 2024

GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review - MSN

Oct 17, 2024

Oct 16, 2024

Is Elevation Oncology Inc (ELEV) worth investing in despite its overvalued state? - US Post News

Oct 16, 2024

Oct 14, 2024

Trading Day Review: Elevation Oncology Inc (ELEV) Gains Momentum, Closing at 0.51 - The Dwinnex

Oct 14, 2024

It is Poised to be a Bull Market for Elevation Oncology Inc (ELEV) - SETE News

Oct 14, 2024

Oct 11, 2024